As demonstrated with several pancreatic cancer cell lines, CBL0137 inhibits NF-κB reporter activity induced by TNF and blocks expression of the endogenous NF-κB targets, IL-8 and TNF, including that which is induced by gemcitabine treatment (Fig.5A, B). The gene discussed is NFKB1; the disease is familial pancreatic carcinoma.